Bausch Health Cos Inc. (NYSE:BHC) Receives $8.33 Average Target Price from Brokerages

Bausch Health Cos Inc. (NYSE:BHC) has earned a consensus recommendation of “Reduce” from the five research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.3333.

A number of brokerages recently commented on BHC. Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Barclays cut their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research report on Thursday, February 19th. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Finally, Truist Financial raised their target price on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors have recently bought and sold shares of the stock. Caption Management LLC boosted its position in Bausch Health Cos by 101.1% during the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after acquiring an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Bausch Health Cos by 12,589.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after acquiring an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares in the last quarter. Finally, Camelot Portfolios LLC purchased a new position in shares of Bausch Health Cos in the 4th quarter valued at approximately $59,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Cos Stock Up 0.1%

NYSE BHC opened at $5.03 on Friday. Bausch Health Cos has a 1 year low of $4.25 and a 1 year high of $8.69. The stock has a market capitalization of $1.87 billion, a PE ratio of 11.96 and a beta of 0.37. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.47 and a quick ratio of 1.08. The business’s 50-day moving average is $5.71 and its 200 day moving average is $6.37.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. The business had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.71 billion. Sell-side analysts forecast that Bausch Health Cos will post 4.41 earnings per share for the current year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.